


CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:
22511Orig1s000**

PROPRIETARY NAME REVIEW(S)



**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology**

Date: April 14, 2010

To: Donna Griebel, MD, Director
Division of Gastroenterology Products

Through: Denise P. Toyer, PharmD, Deputy Director
Division of Medication Error Prevention and Analysis (DMEPA)

From: Laura Pincock, Pharm.D., Acting Team Leader
Division of Medication Error Prevention and Analysis (DMEPA)

Subject: Proprietary Name Review

Drug Name(s): Vimovo (Naproxen and Esomeprazole Magnesium) Tablets
375 mg/20 mg and 500 mg/20 mg

Application Type/Number: NDA 022511

Applicant: Pozen, Inc.

OSE RCM #: 2009-1779

*** This document contains proprietary and confidential information that should not be released to the public. ***

CONTENTS

1	INTRODUCTION.....	3
2	METHODS AND RESULTS.....	3
3	CONCLUSIONS AND RECOMMENDATIONS.....	3
4	REFERENCES.....	4

1 INTRODUCTION

This re-assessment of the proposed proprietary name Vimovo is written in response to the anticipated approval of this NDA within 90 days from the date of this review. DMEPA found the proposed name, Vimovo, acceptable in OSE Review # 2009-1244 dated September 10, 2009. In addition, the Division of Drug Marketing, Advertising and Communications (DDMAC) found the name acceptable from a promotional perspective, and the Division of Gastroenterology Products did not have any concerns with the proposed proprietary name, Vimovo, during our initial review.

2 METHODS AND RESULTS

For the proposed proprietary name, DMEPA staff search a standard set of databases and information sources (see Section 4) to identify names with orthographic and/or phonetic similarity to the proposed name that have been approved since the previous proprietary name review. We used the same search criteria previously used in OSE Review #2009-1244. Because none of the proposed product characteristics were altered we did not re-evaluate previous names of concern. Additionally, DMEPA searched the United States Adopted Names (USAN) stem list to determine if the name contains any USAN stems that may have been added during any USAN updates that occur since the initial assessment of the proposed proprietary name. DMEPA bases the overall risk assessment on the findings of a failure mode and effects analysis (FMEA) of the proposed proprietary name, and focuses on the avoidance of medication errors.

The searches of the databases referenced in Section 4 did not yield any new names thought to look or sound similar to Vimovo and represent a potential source of drug name confusion. Likewise, DMEPA staff did not identify any USAN stems in the proposed proprietary name Vimovo as of April 8, 2010. Accordingly, DMEPA finds the proposed proprietary name Vimovo acceptable for this product.

3 CONCLUSIONS AND RECOMMENDATIONS

The proprietary name risk assessment findings indicate that the proposed name Vimovo is not vulnerable to name confusion that could lead to medication errors nor is the name considered promotional. Thus, the Division of Medication Error Prevention and Analysis (DMEPA) has no objection to the proposed proprietary name Vimovo for this product at this time.

DMEPA considers this a final proprietary name review. However, if approval of the NDA is delayed beyond 90 days from the date of this review, DGP should notify DMEPA because the proposed proprietary name must be re-reviewed prior to the new approval date.

*****This document contains proprietary and confidential information that should not be released to the public.*****

4 REFERENCES

1. OSE Review # 2009-1244 dated September 10, 2009. Proprietary Name Review of Vimovo (Naproxen and Esomeprazole Magnesium) Tablets. Raichell S. Brown, Safety Evaluator.

2. *Drugs@FDA* (<http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm>)

Drugs@FDA contains most of the drug products approved since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present.

Drugs@FDA contains official information about FDA approved [brand name](#), [generic drugs](#), [therapeutic biological products](#), [prescription](#) and [over-the-counter](#) human drugs and [discontinued drugs](#) and “[Chemical Type 6](#)” approvals.

3. *USAN Stems* (<http://www.ama-assn.org/ama1/pub/upload/mm/365/stem-list-cumulative.pdf>)

USAN Stems List contains all the recognized USAN stems.

4. *CDER Proposed Names List*

CDER Proposed Names List is a compiled list of proposed proprietary names submitted to the Division of Medication Error Prevention and Analysis (DMEPA) for review. The list is updated weekly and maintained by DMEPA.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.